Hurler syndrome

Mucopolysaccharidosis I

Mucopolysaccharidosis type II

Hunter syndrome

Enzyme replacement therapy

Transplantation

Mucopolysaccharidosis

Dermatan sulfate

Heparan sulfate

Hematopoietic stem cell transplantation

Mucopolysaccharidosis type I

Lysosomal storage disease

Substrate reduction therapy

Internal medicine

Medicine

Disease

Heparin

Biomolecules

Mucopolysaccharidosis type I (MPS I) is a lysosomal disease, caused by a deficiency of the enzyme alpha-L-iduronidase (IDUA). IDUA catalyzes the degradation of the glycosaminoglycans dermatan and heparan sulfate (DS and HS, respectively). Lack of the enzyme leads to pathologic accumulation of undegraded HS and DS with subsequent disease manifestations in multiple organs. The disease can be divided into severe (Hurler syndrome) and attenuated (Hurler-Scheie, Scheie) forms. Currently approved treatments consist of enzyme replacement therapy (ERT) and/or hematopoietic stem cell transplantation (HSCT). Patients with attenuated disease are often treated with ERT alone, while the recommended therapy for patients with Hurler syndrome consists of HSCT. While these treatments significantly improve disease manifestations and prolong life, a considerable burden of disease remains. Notably, treatment can partially prevent, but not significantly improve, clinical manifestations, necessitating early diagnosis of disease and commencement of treatment. This review discusses these standard therapies and their impact on common disease manifestations in patients with MPS I. Where relevant, results of animal models of MPS I will be included. Finally, we highlight alternative and emerging treatments for the most common disease manifestations.

Mucopolysaccharidosis Type I: Current Treatments, Limitations, and Prospects for Improvement